TME Pharma
TME Pharma N.V. is a clinical-stage German biotechnology company developing proprietary L-RNA aptamer (Spiegelmer) therapeutics that neutralize chemokines in the tumor microenvironment, with lead candidate NOX-A12 in glioblastoma and pancreatic cancer and NOX-E36 in ophthalmology.
- Company typePublic
- Founded1998
- HeadquartersBerlin, Germany
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What TME Pharma does
TME Pharma N.V. (formerly NOXXON Pharma N.V.) is a clinical-stage biotechnology company headquartered in Berlin, Germany, founded in 1997 and publicly listed on Euronext Growth Paris under the ticker ALTME. The company develops biostable aptamers using its proprietary Spiegelmer platform technology — L-stereoisomer RNA/DNA oligonucleotides (mirror-image nucleic acids) that directly bind and neutralize chemokine targets in the extracellular space. The pipeline centers on two clinical-stage candidates: NOX-A12 (olaptesed pegol), a CXCL12 inhibitor in mid-stage development for glioblastoma and pancreatic cancer, and NOX-E36 (emapticap pegol), a CCL2 inhibitor being evaluated for ophthalmology indications through a partnership with the Singapore Eye Research Institute. The company's lead asset, NOX-A12, has demonstrated clinically meaningful activity in the GLORIA Phase 1/2 trial, where combination therapy with radiotherapy and bevacizumab produced median overall survival of 19.9 months versus 9.5 months for standard of care (p=0.003) in newly-diagnosed MGMT-unmethylated glioblastoma — data published in Nature Communications in 2026. NOX-A12 has received FDA Fast Track Designation, FDA Orphan Drug Designation, and EMA Orphan Drug Designation for glioblastoma.
TME Pharma's commercial strategy is partnership-driven rather than independent commercialization. The company is actively pursuing outlicensing of NOX-A12 and NOX-E36, with prior or current collaborations with Merck/MSD (OPTIMUS Phase 2 in pancreatic cancer), the U.S. National Cancer Institute (preclinical brain tumor research), University Hospital Bonn, NCT Heidelberg, and the Singapore Eye Research Institute. Revenue is not generated from product sales; the company's primary funding sources are dilutive equity raises, convertible debt (notably from Atlas Special Opportunities and Kreos Capital/BlackRock), and non-dilutive grants (including a €2.4M German Federal grant for the NOX-A12 Phase 2 trial).
The company employs between 51 and 100 people, has 94,188,981 shares outstanding (June 2025), and reports a cash runway extending to Q2 2027. The most significant recent operational shifts include a CEO transition in June 2025 (Aram Mangasarian from CEO to CSO; Diede van den Ouden as new CEO) and a November 2025 non-binding LOI with a German resource development company to explore diversification into sustainable tailings reprocessing and environmental rehabilitation as a cash-flow-generating side initiative.
TME Pharma firmographics
Firmographics- Name
- TME Pharma
- Legal name
- TME Pharma N.V.
- Website
- https://www.tmepharma.com/
- Company type
- Public
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- TME Pharma N.V. is a clinical-stage German biotechnology company developing proprietary L-RNA aptamer (Spiegelmer) therapeutics that neutralize chemokines in the tumor microenvironment, with lead candidate NOX-A12 in glioblastoma and pancreatic cancer and NOX-E36 in ophthalmology.
- Ownership category
- akta.pro rank
TME Pharma industry classification
Industry- Product category
- Clinical-stage Oncology Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
- akta.pro secondary industry
- Translational Medicine & Biomarkers (HLAIALAF)
Keywords
Where TME Pharma is headquartered
LocationHeadquarters
- HQ city
- Berlin
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
TME Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Outlicensing/partnership deals: TME Pharma is seeking to outlicense its lead compounds NOX-A12 and NOX-E36 to pharmaceutical partners. The company is in active partnership discussions for NOX-A12 licensing with financial runway extending to Q2 2027.
- Strategic transactions: The company is pursuing alternative funding sources including spin-out or strategic transactions for both compounds to achieve positive operational cash flow.
- Government/academic grants: TME Pharma received a €2.4 million German Federal grant to support NOX-A12 Phase 2 trial in brain cancer (October 2024).
- Investment income: The company signed a non-binding LOI with a German resource development company to explore collaboration in sustainable tailings reprocessing and environmental rehabilitation projects as part of its strategy to diversify into cash-flow-generating asset investments.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels7 records
TME Pharma product offering
Product offeringCore offering
TME Pharma is a clinical-stage biotechnology company developing Spiegelmer-based L-RNA aptamer drug candidates that target chemokines in the tumor microenvironment. Its lead candidate NOX-A12 (olaptesed pegol) neutralizes CXCL12 and is in Phase 1/2 development for glioblastoma and Phase 2 for pancreatic cancer, while NOX-E36 (emapticap pegol) neutralizes CCL2 and is being evaluated for ophthalmic anti-fibrotic applications. The company intends to outlicense its candidates to pharmaceutical partners rather than commercialize them directly.
Product overview
TME Pharma is a clinical-stage biotechnology company developing novel therapies for the most aggressive cancers, specializing in approaches targeting the tumor microenvironment (TME). The company's portfolio centers on two Spiegelmer-based drug candidates: NOX-A12 (olaptesed pegol), a CXCL12 inhibitor in mid-stage clinical development for glioblastoma and pancreatic cancer, and NOX-E36 (emapticap pegol), a CCL2 inhibitor being evaluated for ophthalmic diseases. Both candidates work by modulating the tumor microenvironment to break tumor protection barriers against the immune system and block tumor repair. The proprietary Spiegelmer platform technology enables the development of L-RNA aptamers that bind and neutralize chemokine targets in the extracellular space.
Differentiator
Problem solved
Functional benefit
Brands
- Spiegelmer: Proprietary L-RNA aptamer technology platform developed by TME Pharma for generating therapeutic compounds.
- NOX-A12 (olaptesed pegol)
- NOX-E36 (emapticap pegol)
Products and services
- NOX-A12 (olaptesed pegol) NOX-A12 is an intravenously administered, PEGylated L-stereoisomer RNA aptamer (Spiegelmer) that directly binds and neutralizes CXCL12 (C-X-C Chemokine Ligand 12). It is TME Pharma's lead clinical candidate in mid-stage development for glioblastoma (Phase 1/2 GLORIA trial) and pancreatic cancer (Phase 2 OPTIMUS trial with Merck/MSD's Keytruda), working by neutralizing chemokines in the tumor microenvironment to break tumor protection and block tumor repair when combined with radiotherapy and other treatments.
- NOX-E36 (emapticap pegol) NOX-E36 is an injectable PEGylated L-stereoisomer RNA aptamer (Spiegelmer) that directly binds and neutralizes the chemokine CCL2 (MCP-1) and three related chemokines. It has completed Phase 1 and Phase 2 clinical studies and is being evaluated for ophthalmic diseases with high need for anti-fibrotic therapies, particularly in collaboration with the Singapore Eye Research Institute for glaucoma filtration surgery applications.
Quantifiable outcome
- Median overall survival doubled to 19.9 months vs 9.5 months standard of care in glioblastoma patients receiving NOX-A12 + radiotherapy + anti-VEGF
- +5 more outcomes
Companies that use TME Pharma
Customer profileSegments3 records
Ideal customer profiles3 records
TME Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
TME Pharma partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered minor, major and core.
- German Resource Development Company (GRDC)minorTME Pharma signed a non-binding Letter of Intent with a German resource development company to explore potential collaboration and investment in sustainable tailings reprocessing and environmental rehabilitation projects. The deal is part of TME Pharma's strategy to diversify into cash-flow-generating asset investments.
- Singapore Eye Research Institute (SERI)majorTME Pharma signed an option framework agreement with Singapore Eye Research Institute for the ophthalmology development of NOX-E36. The collaboration follows preclinical data published by SERI researchers showing NOX-E36's anti-fibrotic mode of action in an animal model relevant to glaucoma filtration surgery.
- U.S. National Cancer Institute (NCI)coreTME Pharma collaborates with the U.S. National Cancer Institute, part of the National Institutes of Health, to explore the effects of NOX-A12 (CXCL12 inhibitor) and NOX-E36 (CCL2 inhibitor) individually and combined on brain tumors. The research program is led by Dr. Mark R. Gilbert, Chief of the Neuro-Oncology Branch at NCI's Center for Cancer Research. NCI conducts preclinical testing in different combinations with immunomodulatory treatments including immune checkpoint inhibitors in three murine brain cancer models.
- Merck & Co. / MSDcoreTME Pharma and Merck & Co./MSD announced their second clinical collaboration for a Phase 2 trial evaluating NOX-A12 in combination with MSD's anti-PD-1, Keytruda (pembrolizumab), and two different chemotherapy regimens as second-line therapy in patients with microsatellite stable pancreatic cancer. Previously collaborated on OPERA Phase 1/2 trial with Keytruda in metastatic pancreatic and colorectal cancer.
- National Center for Tumor Diseases (NCT) HeidelbergmajorTME Pharma collaborated with Prof. Dr. Dirk Jäger and Dr. Niels Halama at the National Center for Tumor Diseases in Heidelberg, one of Europe's leading centers for cancer research and treatment, to conduct the completed clinical trial in metastatic colorectal and pancreatic cancer.
- University Hospital Bonn (Prof. Dr. Michael Hölzel)coreTME Pharma collaborates with Prof. Dr. Michael Hölzel, Director at the Institute for Experimental Oncology at University Hospital Bonn, on the ongoing GLORIA study. His research focuses on the complexity and dynamics of cellular and non-cellular interactions within the tumor microenvironment with particular focus on neural crest derived tumors. Prof. Hölzel leads research to characterize NOX-A12-mediated modulation of tumor microenvironment in glioblastoma patients by multiparameter immunofluorescence microscopy.
- Prof. Dr. Frank A. GiordanocoreProf. Dr. Frank A. Giordano, Professor and Chair of the Department of Radiation Oncology at the University Medical Center Mannheim, is the lead investigator of the GLORIA trial. He is an expert in precision radiation therapy and intraoperative irradiation of malignant tumors and has received international recognition for his brain tumor research, including an award from ASTRO and honorary membership of SEOR.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
TME Pharma competitors and assessment
Company assessmentEmerging players
- Aprea Therapeutics: Aprea Therapeutics is a US-based clinical-stage oncology company developing small-molecule reactivators of mutant p53. It is a comparable small-cap clinical-stage oncology company with multiple programs, similar partnership-driven strategy, and similar capital-markets dependency.
- Cantargia: Cantargia is a Sweden-based clinical-stage biotech developing antibodies targeting IL1RAP, with oncology programs in pancreatic cancer and other solid tumors. It is a small European clinical-stage oncology company with a similar out-licensing/partnership strategy and tumor-microenvironment-related biology.
- Isofol Medical: Isofol Medical is a Sweden-based clinical-stage oncology company developing arfolitixorin for colorectal cancer. Its former CEO (Dr. Jungnelius) is now TME Pharma's CMO, and both companies share the Nordic/European clinical-stage oncology profile and partnered development model.
- SomaLogic (Standard BioTools): SomaLogic, now part of Standard BioTools, is the leading aptamer-based proteomics company (SOMAmer reagents), directly comparable to TME Pharma's Spiegelmer platform in core technology (modified/aptamer-based molecular recognition), though SomaLogic's commercial focus is diagnostics rather than therapeutics.
Direct peers
- Chimerix: Chimerix is a US clinical-stage oncology company that acquired Oncoceutics (founded by TME Pharma board member Dr. Lee Schalop) for $78M plus milestones in 2021, validating the brain-cancer asset-acquisition model. Chimerix's small-molecule oncology pipeline and focus on CNS tumors make it a relevant strategic comparator.
- X4 Pharmaceuticals: X4 Pharmaceuticals is a commercial-stage biotech developing oral CXCR4 antagonists (mavorixafor, approved for WHIM syndrome; in trials for chronic neutropenia and other indications). It targets the same chemokine receptor pathway as TME Pharma's NOX-A12 (CXCL12/CXCR4 axis), making it the most directly comparable peer in mechanism and therapeutic hypothesis.
- Oncopeptides: Oncopeptides is a clinical-stage/specialty oncology company developing peptide-based therapies for hematological cancers (melflufen/Pepaxto). It is a similarly-sized European clinical-stage oncology company with a novel mechanism of action, comparable in scale, geography, and pipeline-stage dynamics to TME Pharma.
- BioLineRx: BioLineRx developed motixafortide (Aphexda), a CXCR4 antagonist approved in 2023 for stem-cell mobilization in multiple myeloma and explored in pancreatic cancer and other solid tumors. It is the closest late-stage/approved competitor on the CXCR4 mechanism that TME Pharma's NOX-A12 is also pursuing.
- Ryvu Therapeutics: Ryvu Therapeutics is a Poland-based clinical-stage oncology company developing small-molecule kinase inhibitors and immunometabolic therapies. A senior board member of TME Pharma (Dr. Jungnelius) also serves on Ryvu's board, and both companies share the European clinical-stage oncology profile and similar scale.
Others
- NeoVentures Biotechnology: NeoVentures Biotechnology is a Canada-based aptamer technology company developing DNA/RNA aptamers for research, diagnostic, and select therapeutic applications. It is a relevant technology-platform peer to TME Pharma's Spiegelmer platform, though much smaller and with a research-tools focus.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights6 records
Customer concentration
TME Pharma social profiles
Digital presenceTME Pharma compliance and trust
Trust signalCompliance2 records
TME Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
TME Pharma leadership team
Management profileNumber of profiles
Profiles6 records
TME Pharma funding detail
Funding detailFunding overview
Funding rounds17 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TME Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TME Pharma
What does TME Pharma do?
TME Pharma is a clinical-stage biotechnology company developing Spiegelmer-based L-RNA aptamer drug candidates that target chemokines in the tumor microenvironment. Its lead candidate NOX-A12 (olaptesed pegol) neutralizes CXCL12 and is in Phase 1/2 development for glioblastoma and Phase 2 for pancreatic cancer, while NOX-E36 (emapticap pegol) neutralizes CCL2 and is being evaluated for ophthalmic anti-fibrotic applications. The company intends to outlicense its candidates to pharmaceutical partners rather than commercialize them directly.
Is TME Pharma a public or private company?
TME Pharma is a public company. It is classified as public and is currently operating.
When was TME Pharma founded?
TME Pharma was founded in 1998. It employs 51 to 100 people.
Where is TME Pharma based?
TME Pharma is headquartered in Berlin, Germany, in the Europe region.
How does TME Pharma make money?
Four revenue lines are on record. Outlicensing/partnership deals are the primary driver. The others are strategic transactions, government/academic grants and investment income.
Who are TME Pharma's main competitors?
Emerging players on record are Aprea Therapeutics, Cantargia, Isofol Medical and SomaLogic (Standard BioTools). Direct peers are Chimerix, X4 Pharmaceuticals, Oncopeptides, BioLineRx and Ryvu Therapeutics. NeoVentures Biotechnology is listed as an others.
Does TME Pharma have an API?
No public API is recorded for TME Pharma.
What industry is TME Pharma in?
TME Pharma's product category is Clinical-stage Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 325412 and its SIC code is 2834.